NCT06911554View on ClinicalTrials.gov

A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites

PHASE3CompletedINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions
Hepatic Ascites
Interventions
BIOLOGICAL

Recombinant Human Albumin Injection

Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.

BIOLOGICAL

Human Albumin

Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

Tonghua Anrate Biopharmaceutical Co., Ltd.

INDUSTRY